4.5 Article

Commercially available antibodies directed against α-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments

Journal

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Volume 389, Issue 2, Pages 243-248

Publisher

SPRINGER
DOI: 10.1007/s00210-015-1196-0

Keywords

Selective antibodies; Alpha adrenergic receptors; Vasopressin receptor; Chemokine receptor

Funding

  1. National Institute of General Medical Sciences [R01GM107495, T32GM008750]
  2. National Cancer Institute [R01CA135341, R01CA188427]
  3. National Heart, Lung, and Blood Institute [R21HL118588]
  4. U.S. Army Medical Research and Materiel Command (USAMRMC)/Medical Research Acquisition Activity (USAMRAA) at Fort Detrick, MD [W81XWH-15-1-0262]

Ask authors/readers for more resources

Several previous reports suggested that many commercially available antibodies directed against G protein-coupled receptors (GPCR) lack sufficient selectivity. Accordingly, it has been proposed that receptor antibodies should be validated by at least one of several criteria, such as testing tissues or cells after knockout or silencing of the corresponding gene. Here, we tested whether 12 commercially available antibodies directed against alpha-adrenergic receptor (AR) subtypes (alpha(1A/B/D), alpha(2A/B/C)), atypical chemokine receptor 3 (ACKR3), and vasopressin receptor 1A (AVPR1A) suffice these criteria. We detected in flow cytometry experiments with human vascular smooth muscle cells that the fluorescence signals from each of these antibodies were reduced by 46 +/- A 10 %-91 +/- A 2 % in cells treated with commercially available small interfering RNA (siRNA) specific for each receptor, as compared with cells that were incubated with non-targeting siRNA. The tested antibodies included anti-ACKR3 (R&D Systems, mab42273), for which specificity has previously been demonstrated. Staining with this antibody resulted in 72 +/- A 5 % reduction of the fluorescence signal after ACKR3 siRNA treatment. Furthermore, staining with anti-alpha(1A)-AR (Santa Cruz, sc1477) and anti-ACKR3 (Abcam, ab38089), which have previously been reported to be non-specific, resulted in 70 +/- A 19 % and 80 +/- A 4 % loss of the fluorescence signal after alpha(1A)-AR and ACKR3 siRNA treatment, respectively. Our findings demonstrate that the tested antibodies show reasonable selectivity for their receptor target under our experimental conditions. Furthermore, our observations suggest that the selectivity of GPCR antibodies depends on the method for which the antibody is employed, the species from which cells/tissues are obtained, and on the type of specimens (cell, tissue/cell homogenate, or section) tested.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available